Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

Scope is limited to digital biomarkers usage in Clinical Trials

Problem Statement

Digital biomarkers are defined as objective, quantifiable physiological and behavioural data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles. As an emerging technology, Digital Biomarkers ability in addressing medical challenges is enormous. Project “DB360”, to focus on all areas surrounding Digital Biomarkers and its usage in clinical trials. You can find further information here.

Problem Impact

This project identifies current state of digital biomarkers in clinical sector and its future impact. It will cover the topics: Classification of existing digital biomarkers, Clinical Therapeutic areas where digital biomarkers usage is progressing, limitations, etc., Stakeholders impacted are Pharma, CROs, tech companies, regulators and SDOs. “DB360” will be built on the paper DH08 submitted in PHUSE US Connect 2020 with final

The project will introduce and identify the current state of topics relating to the usage of digital health technologies in clinical trials and regulatory submissions:

  • The use of DHT in the clinical space
  • Continuous data flow from telemedicine and telehealth platforms, mobile health (mHealth), wearable/implantable devices, software as a medical device (SaMD)
  • Clinical and analytical validation of medical devices
  • Digital biomarkers, digital interventions and digital medicine

The project will also provide a common platform to discuss regulatory guidance around DHT.


Problem Statement 

Digital biomarkers cannot be explained without providing context to the larger eco-system of digital health technology (DHT). Digital health technology has been growing rapidly in recent years, and this trend is expected to continue. The COVID-19 pandemic has also accelerated the adoption of digital health technologies as people have become more accustomed to receiving healthcare services remotely.


Problem Impact 

We are requesting to change the Digital Biomarker Working Group project with Digital Health Technology. Navigating the regulatory landscape for digital health technologies can be challenging. Companies need to be proactive in understanding the regulatory requirements that apply to their products and work closely with regulators to ensure they are meeting these requirements in a timely and efficient manner.

outcome of White Paper and presentations at PHUSE conferences in 2022



Project LeadsEmail
Vijay Pasapula
(
, Cerus
)
VPasapula@cerus.com
Unnat Patel
(
, AnalysisMate
)
unnat.patel@analysismate.com
Katie Warren (
Kerry Robson, PHUSE Project Assistant
)
katie@phuse

kerry@phuse.global

 Objectives & DeliverablesTimelinesDraft White Paper

Q42022

PHUSE Connect 2022 poster and presentation recording 

Q22022

Determination of sub-topics to expand further

Q32022

Draft of few sub-topics for White Paper

Q42022


Status
colourBlue
titleCurrent Status

Q12022
  • Developing sub-topics for a White Paper presentation which will be focused on identifying issues such as data sources, RWE technologies, data privacy and related issues, and standards
  • Poster abstract approval for the PHUSE Connect 2022 
  • Sub-topics research expanded

Q1 2024

White paper on digital health technologies



Objectives & DeliverablesTimelines
Produce a poster / paper for US Connect

Q1 2024 

Produce a White Paper

Q3 2024 

Deliver a presentation at a PHUSE Single Day Event on DHTs

Q3 2023

Project MembersOrganisationErin ErginerPinnacle 21Gianna HuangGilead Sciences Ippei AkiyaA2 Healthcare CorporationJing SuMerckKunal BanshingeSpringer NatureLavanya Sundaram

Sanofi

Manohara HalasiddappaAlgok BioNaseem Buckley TakedaNeetu SangariPfizerSathish Kumar ChittaVeranex Solutions

Subhayan Das

Bristol Myers SquibbSudeepa DuttaICON DOCSSungHo LimGenentechTao GuGilead SciencesTeckla AkinyiGSKUnnat Patel AnalysisMate

Zahra Karimaddini

Roche